Replies to post #149525 on Biotech Values

[DewDiligence]

MNTA—It is possible that the share price thresholds that the execs set out in their [10b5-1] plans simply have not been met.

No. If you examine a MNTA price chart in conjunction with the list of Form-4 filings in the embedded link in #msg-79723828, you’ll see that the above hypothesis for the lack of 10b5-1 sales in September must be rejected.